《 商业观察 》 记者倪寒飞、靳星星 上海报道 3·15报道｜柏荟医疗的转型阵痛：当"高定美学"遭遇渠道 漩涡 "这提成油水太多了，得拿麻袋装！"网友的讽刺并非空穴来风。有媒体报道，柏荟医疗的"渠道商"涵盖美甲店、 减肥中心甚至KTV，这些合作方每推荐一位客户，可获得30%～40%的返佣。以一支原价8800元的瑞蓝2号玻尿酸 为例，通过渠道打包价仅需4980元，差价部分则由合作方与柏荟医疗分成。 业内人士指出，在柏荟医疗的商业模式中，渠道合作方通过"拉客提成"机制参与利益分配，部分渠道的返佣比例 高达50%以上。这种模式直接推高了医美服务的终端价格，形成了"羊毛出在羊身上"的恶性循环。以温州柏荟医 疗美容门诊部有限公司为例，其单客消费金额中，近半数需用于支付渠道费用，最终导致消费者承担较高成本。 对于消费者而言，高额提成往往意味着消费风险的增大。为了获取更多提成，销售人员可能会夸大医美项目的功 效，隐瞒潜在的风险，诱导消费者进行一些不必要的甚至不适合自身情况的医美消费。在信息不对称的情况下， 消费者很容易做出错误的决策，不仅可能花费大量金钱却无法达到预期效果，还可能因不当的医美操作而面临健 康威胁。 2025 ...

京圈美丽地标跨界奔赴 北京美莱THEBOX快闪店 即将亮相 2025年3月28日，北京美莱医疗美容医院与THE BOX朝外年轻力中心联合打造的"「认真」美貌充电 站"快闪店即将限时开启。据悉，本次快闪店的设置背景是北京美莱第6季莱粉嘉年华「把认真做到成 真」，是北京美莱一年一度回馈会员的品牌盛会，延续「认真」这一嘉年华主题，限时营业10天 的"「认真」美貌充电站"融合黑科技、专业美学与限时福利的沉浸式变美空间，并邀请知名男神博主作 为一日店长现场站台，在设计和规划上做到了认真的筹备，是北京美莱全力迎合中国消费结构迭代后， 满足新生年轻族群需求多元化的全新营销尝试。 医美入局Pop-up shop 北京美莱品牌年轻化变局新起点 快闪店，也称为Pop-up shop或temporary store的品牌游击店(Guerrilla Store)，在英语中有"突然弹出"之 意，是品牌方在发达商圈设置的临时铺位，在较短的时间短精准触达某类消费群体的营销形式。而在营 销模式一直以来相对拘谨的医美行业，在面对中国消费结构迭代，年轻族群逐渐占据主导的趋势下，也 开始积极拥抱更加多元化的营销形式。 本次"「认真」美貌充电站"不 ...

Investment Rating - The report maintains a "Recommendation" rating for the company, indicating an expectation that the stock will outperform the market by 10% to 20% over the next six months [1][13]. Core Views - Despite macroeconomic impacts, the company's performance remains robust, with a projected revenue of 30.26 billion yuan in 2024, reflecting a year-on-year growth of 5.45%. The net profit is expected to grow by 5.33% to 19.58 billion yuan [1][3]. - The company is focusing on expanding its product line and has made significant progress in its product pipeline, including the approval of several medical devices and clinical trial applications [1][5]. - The company is enhancing its operational capabilities through digital platform development and supply chain improvements, which are expected to drive future growth [1][11]. Financial Summary - In 2024, the company anticipates a revenue of 30.26 billion yuan, with a net profit of 19.58 billion yuan, and a basic EPS of 6.5 yuan. The cash flow from operating activities is projected to be 19.27 billion yuan [1][4]. - The company reported a decline in Q4 revenue by 7% to 6.5 billion yuan, with a net profit decrease of 15.47% to 3.72 billion yuan. The gross margin for the quarter was 94.03%, and the net margin was 57.09% [4][9]. - The company’s financial projections for 2025 estimate revenues of 34.79 billion yuan and net profits of 22.09 billion yuan, with a corresponding P/E ratio of 26.6 [6][12].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [4][12]. Core Insights - In 2024, the company achieved revenue of 3.026 billion RMB, a year-on-year increase of 5.5%, and a net profit attributable to shareholders of 1.958 billion RMB, up 5.3% year-on-year [1]. - The company is experiencing a mixed performance in its product lines, with injection gel and solution products showing growth despite a weak overall market demand in the medical aesthetics sector [2]. - The company has made significant progress in its product pipeline, with multiple research and development projects advancing, which lays a foundation for future growth [3]. Financial Performance - The company reported a revenue of 30.26 billion RMB in 2024, with a net profit of 19.58 billion RMB, and a non-recurring net profit of 18.72 billion RMB [1]. - For the fourth quarter of 2024, the company recorded a revenue of 6.5 billion RMB, a decrease of 7% year-on-year, and a net profit of 3.72 billion RMB, down 15.5% year-on-year [1]. - The revenue from solution injection products was 17.44 billion RMB, growing by 4.4% year-on-year, while gel injection products generated 12.16 billion RMB, up 5.01% year-on-year [2]. Profit Forecast and Valuation - The profit forecast for 2025-2027 estimates net profits of 2.381 billion RMB, 2.874 billion RMB, and 3.368 billion RMB, representing year-on-year growth rates of 22%, 21%, and 17% respectively [4]. - The earnings per share (EPS) for the same period are projected to be 7.87 RMB, 9.50 RMB, and 11.13 RMB, with corresponding price-to-earnings (P/E) ratios of 24, 20, and 17 [4].

Investment Rating - The report maintains a "Recommended" rating for the company [4][6][10]. Core Insights - The company achieved a revenue of 3.026 billion yuan in 2024, representing a year-on-year growth of 5.45%, and a net profit attributable to shareholders of 1.958 billion yuan, up 5.33% year-on-year [1][4]. - The acquisition of REGEN Biotech for 190 million USD is a strategic move to enhance the company's competitive edge and international presence in the aesthetic medicine market [2][3]. - The company has a robust pipeline of products, with several expected to launch soon, indicating strong growth potential in the medium to long term [3][4]. Financial Performance Summary - **Revenue and Profit Forecasts**: - 2024 Revenue: 3.026 billion yuan, 2025 Revenue: 3.390 billion yuan (12.0% growth), 2026 Revenue: 3.911 billion yuan (15.4% growth), 2027 Revenue: 4.777 billion yuan (22.1% growth) [4][6]. - 2024 Net Profit: 1.958 billion yuan, 2025 Net Profit: 2.198 billion yuan (12.3% growth), 2026 Net Profit: 2.567 billion yuan (16.8% growth), 2027 Net Profit: 3.168 billion yuan (23.4% growth) [4][6]. - **Valuation Metrics**: - PE ratios for 2025, 2026, and 2027 are projected at 26X, 22X, and 18X respectively [4][6]. - The company’s net profit margin for 2024 is 64.66%, with a slight increase expected in subsequent years [1][6].

Core Viewpoint - The article highlights the rising consumption power and changing attitudes of middle-aged men towards self-investment, particularly in health and grooming products, indicating a shift in the male consumer market [3][31][39]. Group 1: Changing Male Consumption Trends - Successful men are increasingly willing to spend on high-end health products, such as the "president bowl" bird's nest priced at 528 yuan per bowl, reflecting a broader trend of men investing in their well-being [3][4][31]. - The male health and grooming market is experiencing significant growth, with the male high-end health product market size increasing by 47% year-on-year, and men over 40 contributing over 60% of sales [28][31]. - The male skincare and medical beauty market is growing rapidly, with a reported annual growth rate exceeding 20% and average spending per customer reaching 2.75 times that of female customers [26][31]. Group 2: Consumer Behavior Insights - Men are now prioritizing visible benefits in their purchases, such as energy enhancement and anti-aging, leading brands to emphasize "hardcore technology" in their products [29][31]. - Social media platforms are playing a crucial role in shaping male consumer behavior, with discussions around men's health and skincare increasing significantly, indicating a shift in societal norms [32][33]. - The emergence of brands catering specifically to men's needs, such as "Kehan" for skincare, demonstrates the growing market potential and the willingness of men to invest in personal care [22][25]. Group 3: Market Implications - The changing dynamics in male spending habits suggest that the era of men only purchasing luxury items like watches and cars is over, with a new focus on health and self-care [31][39]. - The success of brands like "Xiaoguan Tea," which achieved annual revenue of 2 billion yuan, illustrates the lucrative opportunities in the male consumer market [20][31]. - The article suggests that as more men embrace self-care and grooming, the market will likely see the introduction of products that surpass traditional luxury offerings, indicating a potential shift in the overall health and beauty industry [42].

Investment Rating - The report maintains a "Buy" rating for the company [5][8]. Core Insights - The company reported a revenue of 3.03 billion yuan for 2024, reflecting a year-on-year growth of 5.4%, while the net profit attributable to shareholders was 1.96 billion yuan, also up by 5.3% [5][8]. - The fourth quarter of 2024 saw a decline in revenue to 650 million yuan, down 7.0% year-on-year, and a net profit of 370 million yuan, down 15.5% year-on-year [5][8]. - The company plans to distribute a cash dividend of 38 yuan for every 10 shares to all shareholders [5]. Summary by Sections Financial Performance - Revenue from solution products and gel products for 2024 was 1.74 billion yuan and 1.22 billion yuan, respectively, with year-on-year growth of 4.4% and 5.0% [6]. - The sales volume for solution products was 634.6 thousand units, up 23.4%, while gel products saw a decline in sales volume by 11.2% to 89.4 thousand units [6]. - The overall gross margin for the company decreased by 0.5 percentage points to 94.6%, while the net profit margin decreased by 0.1 percentage points to 64.7% [6][8]. R&D and Product Development - The company increased its R&D investment, completing 57 patent applications and engaging in 21 research projects with various medical institutions [7]. - New products are expected to enhance the gel product line, including a medical gel for chin augmentation and other injectable products that have received clinical trial approvals [7][8]. M&A and Market Expansion - The company plans to acquire AestheFill's source company, REGEN Biotech, Inc., which is expected to enhance its competitive advantage in the global regenerative market and strengthen its overseas market expansion capabilities [8]. - The report anticipates that the combination of mergers and acquisitions along with overseas expansion will provide new growth points for the company [8]. Financial Projections - Revenue projections for 2025 and 2026 have been adjusted to 3.213 billion yuan and 3.837 billion yuan, reflecting downward revisions of 15% and 17% respectively [8]. - The expected net profit for 2025 and 2026 is projected to be 2.062 billion yuan and 2.448 billion yuan, also down by 15% for both years [8]. - The report introduces a new revenue and net profit forecast for 2027 at 4.425 billion yuan and 2.814 billion yuan, respectively [8].

Macro and Strategy - The Federal Reserve maintained the federal funds rate target range at 4.25-4.5% and announced a slowdown in balance sheet reduction, lowering the monthly limit for Treasury redemptions from $25 billion to $5 billion [7] - The high-tech manufacturing macro report indicates that the diffusion index for high-tech manufacturing remains stable, with a slight decline in certain sectors such as aerospace and new energy [7][8] - The AI-enabled asset allocation strategy highlights the integration of ESG factors into traditional investment theories, suggesting that incorporating ESG constraints can enhance portfolio performance [9][10] Industry and Company Insights - The social services sector is expected to benefit from recent consumption policies aimed at boosting domestic demand, with a focus on service consumption [10][11] - Data tracking shows a positive trend in retail sales and hiring demand, indicating a gradual economic recovery [11][12] - The textile and apparel sector has seen a rebound in retail sales growth, with notable increases in exports from Vietnam [13][14] - China Unicom reported a 10.5% year-on-year increase in net profit for 2024, with a focus on innovative business growth and a stable traditional business [16][17] - Xingyu Co. achieved a 34% year-on-year increase in net profit for Q4 2024, driven by strong demand for automotive lighting products [21][22] - Xtep International reported a 20% increase in net profit for 2024, with significant growth in its professional sports brand [24][25] - Anta Sports saw a 16.5% increase in core profit for 2024, supported by a diverse brand portfolio [28][29] - ZhongAn Online's total premium income reached 33.42 billion yuan in 2024, with a 13.3% year-on-year growth, driven by its diversified product ecosystem [30][31] - Ping An Insurance reported a 47.8% year-on-year increase in net profit for 2024, supported by a robust strategic layout in comprehensive finance and healthcare [33][34]

Group 1: Company Strategy and Focus - The company remains focused on its core business and aims to serve downstream customers effectively [2] - The company will not establish flagship hospitals like competitors to directly engage with users [2] - The company emphasizes maintaining sustainable growth and shareholder value [7] Group 2: Financial Performance and Projections - In 2024, the company achieved a revenue of CNY 3.03 billion, with a net profit of CNY 1.96 billion, reflecting a year-on-year growth of 5.5% and 5.3% respectively [18] - The company anticipates a significant increase in performance following the acquisition of REGEN Biotech, with production expected to start in Q2 2025 [16] - The company’s overseas revenue is currently CNY 1.58 million, accounting for only 0.05% of total revenue [2] Group 3: Product Development and Market Expansion - A new product, a medical-grade polyvinyl alcohol gel microsphere, has received regulatory approval and is set to launch in 2025 [12] - The company plans to expand its product line to cater to younger consumer demographics while maintaining quality [20] - The company is exploring mergers and acquisitions to enhance its product offerings and competitiveness [19] Group 4: Challenges and Market Conditions - The company faces intense competition in the medical aesthetics sector, which has led to a slowdown in growth [2] - Operating cash flow has seen a decline of 1.38%, with cash inflow increasing by 8.9% but outflow rising by 27% due to various operational costs [18] - The company acknowledges the challenges posed by market conditions and is considering strategies to regain investor confidence [19]

Core Viewpoint - The company reported a steady growth in revenue and net profit for 2024 despite industry pressures, with a revenue of 3.03 billion and a net profit of 1.96 billion, reflecting year-on-year increases of 5.4% and 5.3% respectively [2][3] Revenue and Profit Analysis - In Q4 2024, the company's revenue was 650 million, showing a year-on-year decline of 7.0%, while the net profit was 370 million, down 15.5% year-on-year [2] - The revenue from solution products and gel products for 2024 was 1.74 billion and 1.22 billion respectively, with year-on-year growth of 4.4% and 5.0% [3] Product Performance - The sales volume for solution products was 634.6 thousand units, up 23.4% year-on-year, while gel products saw a decline in sales volume to 89.4 thousand units, down 11.2% [3] - The average price of solution products decreased due to a shift in product mix, while the average price of gel products increased due to a higher proportion of high-margin products [3] Profitability Metrics - The company's gross margin for 2024 was 94.6%, a decrease of 0.5 percentage points year-on-year, while the net profit margin was 64.7%, down 0.1 percentage points [4] - In Q4 2024, the gross margin was 94.0%, down 0.4 percentage points year-on-year, and the net profit margin was 57.2%, down 5.7 percentage points [4] R&D and Cost Management - The company increased its R&D investment, with a R&D expense ratio significantly rising, completing 57 patent applications and engaging in 21 collaborative research projects with medical institutions [4] - The overall expense ratio increased by 1.3 percentage points to 22.2%, driven by higher R&D costs, while sales expenses remained stable [4] Product Line Expansion - The company received a Class III medical device registration for a new gel product, expected to launch this year, which will enhance its gel product line [5] - Clinical trial approvals were obtained for several new products, indicating ongoing innovation and product development [5] Strategic Acquisition - The company plans to acquire REGEN Biotech, Inc. in March 2025, which is expected to strengthen its competitive advantage in the global regenerative market and enhance its overseas market expansion capabilities [7]